TIDES Europe:
Codexis Presentation Overview

November 2024

CODEXIS®

Forward Looking Statements

These slides contain forward-looking statements that involve risks and uncertainties. These statements relate to future events or our future financial or operational performance and involve known and unknown risks, uncertainties and other factors that could cause our actual results or levels of activity, performance or achievement to differ materially from those expressed or implied by these forward-looking statements. In some cases, you can identify forward-looking statements by terms such as “may,” “will,” “should,” “could,” “would,” “expects,” “plans,” “anticipates,” “believes,” “estimates,” “projects,” “predicts,” “potential” or the negative of these terms, and similar expressions and comparable terminology intended to identify forward-looking statements. In addition, forward-looking statements include all statements that are not historical facts including, but not limited to, the potential of the Company’s ECO Synthesis™ platform and double-stranded RNA (dsRNA) ligase screening and optimization services to meet future customer needs and to create value for Codexis and its customers by enabling commercial-scale manufacture of RNAi therapeutics; anticipated technical and commercial milestones related to the ECO Synthesis™ platform and the dsRNA ligase program, and public announcements related thereto; the potential for the Company’s dsRNA ligases to improve manufacturing scalability and yield compared to wild types or non-ligation methods, and for the Company’s ligase offerings to show more versatility in meeting future customer needs; potential details and features of the ECO Synthesis™ platform such as it being scalable and efficient, as well as having broad applicability to meet future customer needs. These forward-looking statements represent our estimates and assumptions only as of the date hereof, and, except as required by law, Codexis undertakes no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise.

Actual results could differ materially from Codexis' current expectations for a variety of reasons, including due to the factors set forth in Codexis’ most recently filed periodic report, including under the caption “Risk Factors,” and Codexis’ other current and periodic reports filed with the SEC. If any of these risks or uncertainties materialize, or if Codexis’ underlying assumptions prove to be incorrect, actual results or levels of activity, performance or achievement, or any of the foregoing forward-looking statements, may vary significantly from what Codexis projected.

CODEXIS®

TIDES Europe: Key Highlights

- **Successfully Made Inclisiran using the ECO Synthesis™ Platform**
  - First ever end-to-end enzymatic synthesis of a complete siRNA therapeutic
- **Synthesized Inclisiran using Four Different Enzymatic Methods**
  - Illustrates flexibility and reliability of ECO Synthesis platform
- **Completed Multiple Proof-of-Concept Technical Collaborations**
  - Bachem
  - Major siRNA drug innovator

CODEXIS®

TIDES Europe: Three Codexis Presentations

Joint Poster Presentation

- Demonstrate superior performance of Codexis double-stranded RNA ligase variant over wild-type enzyme with

BACHEM

Oral Presentation #1

- Showcase data from double-stranded RNA ligase customer case studies to highlight the benefits of ligase engineering and process optimization

Oral Presentation #2

- Compare various routes of enzymatic synthesis using the ECO Synthesis platform to manufacture a commercially approved siRNA therapeutic (inclisiran)

CODEXIS®

Joint Poster Presentation with Bachem

Data Provides Compelling External Validation of Superior Performance of Codexis Double-Stranded RNA Ligase Variant Over Wild-Type Enzymes

Codexis Double-Stranded RNA Ligase Demonstrates:

- **Higher Volumetric Productivity**
  - Enables manufacture of more siRNA drug substance with less enzyme
  - Exhibits faster and higher conversion of oligonucleotide fragments into full-length siRNA
  - Sets the stage for meaningful improvements in scalability
- **Greater Substrate Versatility**
  - Works across broad range of modified RNA building blocks used in siRNA today
  - Drives a more robust, higher-yielding manufacturing process
  - Positions ligase as a potential platform technology by enabling assembly of multiple siRNA assets using just one Codexis enzyme

CODEXIS®

Oral Presentation #1:
Ligase Screening & Optimization Service Case Studies

Double-Stranded RNA Ligase Customer Case Studies Highlight Benefits of Enzyme Engineering and Process Optimization

Ligase Screening & Optimization Service:

- **Accelerates Delivery of Lead Ligase Variants to Customers by Leveraging Codexis':**
  - Extensive libraries of engineered enzymes
  - Longstanding expertise in optimizing process conditions for a specific asset
- **Delivers Robust, In-Process Ligase Performance**
  - Higher substrate loading
  - Faster reaction times
  - Improved conversion of oligo fragments into siRNA at elevated temperatures

CODEXIS®

Oral Presentation #2:
Comparing Synthesis of Inclisiran Using Four Different Enzymatic Routes

Synthesis Routes
Sequential enzymatic synthesis of full-length siRNA asset using ECO Synthesis technology
Ligation of fragments produced by ECO Synthesis technology
Ligation of fragments produced by ECO Synthesis technology & chemical methods
Ligation of fragments produced by chemical methods

Key Takeaways:

- Codexis presented first-ever enzymatic synthesis of an entire approved siRNA therapeutic (inclisiran)
- Ligation using both enzymatically and chemically produced fragments resulted in full-length siRNA oligos of equal quality and yields
- Core ECO Synthesis technology achieved >98% coupling efficiency, in-line with chemical methods
- Data demonstrates broad applicability of enzymes in siRNA synthesis

Codexis has Demonstrated Process Development Capabilities for a Variety of Routes of Enzymatic siRNA Synthesis

CODEXIS®

Codexis at TIDES Europe



Nasdaq: **CDXS**
www.codexis.com

CODEXIS®